Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
10.73
+1.21 (12.71%)
At close: Jun 26, 2026, 4:00 PM EDT
10.90
+0.17 (1.58%)
After-hours: Jun 26, 2026, 7:53 PM EDT

Akari Therapeutics, Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
4.439.289.6611.36-13.088.08
Research & Development
0.922.826.985.45-10.829.13
Other Operating Expenses
8.435.185---
Total Operating Expenses
13.7717.2821.6416.81-23.8917.21
Operating Income
-29.51-17.28-21.64-16.8123.89-17.21
Interest Income
000.010.08-0.01
Interest Expense
-0.96-0.95-0.24---
Other Non-Operating Income (Expense)
2.98-0.082.096.724.41-0.22
Total Non-Operating Income (Expense)
2.03-1.031.856.84.41-0.21
Pretax Income
-27.48-18.3-19.79-10.0128.3-17.42
Provision for Income Taxes
--1---2.47-
Net Income
-8.3-17.3-19.79-10.01-17.01-17.42
Net Income to Common
-8.3-17.3-19.79-10.01-17.01-17.42
Shares Outstanding (Basic)
111000
Shares Outstanding (Diluted)
111000
Shares Change (YoY)
58.55%70.22%443.33%56.79%45.46%35.87%
EPS (Basic)
-7.25-15.28-29.77---328.00
EPS (Diluted)
-7.25-15.28-29.77---328.00
Free Cash Flow
-10.91-10.57-12.55-4.76-7.63-18.85
Free Cash Flow Per Share
-9.53-9.34-18.88-38.88-97.74-351.29
EBITDA
-29.51-17.28-21.63-16.4924.68-17.21
EBIT
-29.51-17.28-21.64-16.8123.89-17.21
Effective Tax Rate
-5.48%0.00%0.00%-8.74%0.00%
SEC Filings: 10-K · 10-Q